In vivo-directed evolution identifies AAV-WM04 as a next-generation vector for potent and sustained hearing restoration in DFNB9
Molecular Therapy · 2026-10 · 34 (10) · 5726-5744
DOI: 10.1016/j.ymthe.2026.07.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-10. Verfasst von Yong Tao und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R…. Hauptthemen laut MEDLINE: Dependovirus, Genetic Vectors, Genetic Therapy, Directed Molecular Evolution. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China Stem Cell and Translational Research, National Natural Science Foundation of China.
Abstract (Originalsprache)
Efficient and cell-specific gene delivery to cochlear inner hair cells (IHCs) remains a major challenge for inner ear gene therapy. Here, we identify and characterize a novel adeno-associated virus (AAV)2-derived capsid, AAV-WM04, that enables highly efficient and selective IHC transduction at low doses. Using an in-vivo-directed evolution strategy, we generated a randomized AAV2 capsid library with 9 amino acid insertions and performed iterative selection in the adult mouse cochlea. Next-generation sequencing revealed enrichment of several variants, among which AAV-WM04 exhibited superior packaging efficiency and pronounced IHC tropism. AAV-WM04 achieved near-complete IHC transduction throughout the cochlear axis in adult mice, outperforming clinically relevant vectors with minimal off-target expression and no detectable ototoxicity. Selective IHC transduction was observed in non-human primates following local delivery, providing proof-of-concept evidence supporting the translational potential of AAV-WM04. Therapeutically, AAV-WM04 enabled efficient dual-AAV trans-splicing delivery of the large OTOF gene, resulting in uniform full-length otoferlin expression in IHCs. In a humanized OtofQ829X/Q829X mouse model, AAV-WM04 restored auditory function across a broad frequency range at relatively low doses and achieved sustained hearing recovery. These findings establish AAV-WM04 as a next-generation IHC-targeted vector with high efficiency, safety, and cross-species applicability for precision gene therapy of hereditary hearing loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China; Department of Audiology & Speech-Language Pathology, College…
- Shanghai EmayGene Technology Co., Ltd., Shanghai, China; EmayGene (Suzhou) Biotechnology Co., Ltd., Suzhou, China.
- Shanghai Obio Technology (Group) Corp., Ltd., Shanghai, China.
- Shanghai EmayGene Technology Co., Ltd., Shanghai, China.
- iHuman Institute, ShanghaiTech University, Shanghai, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
- iHuman Institute, ShanghaiTech University, Shanghai, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, China. Electronic address: zhongsh@shanghaitech.edu.cn.
Förderung
- National Key Research and Development Program of China Stem Cell and Translational Research
- National Natural Science Foundation of China
Zitieren
APA
Tao, Y., Chu, C., Cheng, Z., Yin, S., Sun, Y., Chen, Y., Zhang, H., Bao, S., Yang, B., Feng, B., Huang, X., Lu, Y., Yang, Q., Mao, X., Zhou, Q., Jin, C., Duan, Z., Zhong, G., & Wu, H. (2026). In vivo-directed evolution identifies AAV-WM04 as a next-generation vector for potent and sustained hearing restoration in DFNB9. Molecular Therapy, 34(10), 5726-5744. https://doi.org/10.1016/j.ymthe.2026.07.021
Vancouver
Tao Y, Chu C, Cheng Z, Yin S, Sun Y, Chen Y, et al. In vivo-directed evolution identifies AAV-WM04 as a next-generation vector for potent and sustained hearing restoration in DFNB9. Molecular Therapy. 2026;34(10):5726-5744. doi:10.1016/j.ymthe.2026.07.021
BibTeX
@article{Tao2026,
author = {Tao, Yong and Chu, Cenfeng and Cheng, Zhenzhe and Yin, Shan and Sun, Yilin and Chen, Ying and Zhang, Huifang and Bao, Shuyue and Yang, Boyu and Feng, Baoyi and Huang, Xianyu and Lu, Yao and Yang, Qiuxiang and Mao, Xuegao and Zhou, Qifang and Jin, Chenxi and Duan, Zhuo and Zhong, Guisheng and Wu, Hao},
title = {In vivo-directed evolution identifies AAV-WM04 as a next-generation vector for potent and sustained hearing restoration in DFNB9},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {10},
pages = {5726--5744},
doi = {10.1016/j.ymthe.2026.07.021}
}
EUVIMED